

# Cognitive Deficits in Patients With Antiphospholipid Sy

Archives of Internal Medicine

166, 2278

DOI: [10.1001/archinte.166.20.2278](https://doi.org/10.1001/archinte.166.20.2278)

Citation Report

#	ARTICLE	IF	CITATIONS
1	What matters in white matter dementia?. <i>Dementia E Neuropsychologia</i> , 2007, 1, 131-139.	0.8	4
2	Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. <i>Journal of Neuroimmunology</i> , 2007, 190, 151-156.	2.3	24
3	A case of catastrophic antiphospholipid syndrome presenting with acute respiratory distress syndrome as the initial manifestation. <i>Rheumatology International</i> , 2008, 29, 211-216.	3.0	7
4	The antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 831-845.	3.3	15
5	Primary Antiphospholipid Syndrome Unusual Presentation in a Seventy Two Year Old Man. <i>Libyan Journal of Medicine</i> , 2008, 3, 106-107.	1.6	2
6	Antiphospholipid (Hughes) syndrome: beyond pregnancy morbidity and thrombosis. <i>Journal of Autoimmune Diseases</i> , 2009, 6, 3.	1.0	10
7	Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 109-125.	6.5	30
8	Chapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, 10, 215-234.	0.1	0
9	Chapter 19 Future of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 235-241.	0.1	1
10	Clinical implications of neuropsychiatric systemic lupus erythematosus. <i>Advances in Psychiatric Treatment</i> , 2009, 15, 451-458.	0.5	26
11	The Pathogenesis of Neural Injury in Animal Models of the Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 196-200.	6.5	45
12	The Antiphospholipid Syndrome as a Neurological Disease. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 97-108.	3.4	54
13	Cerebral lesions in patients with connective tissue diseases and systemic vasculitides: are there specific patterns?. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 167-175.	3.8	11
14	Non-criteria manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2010, 19, 424-427.	1.6	62
16	Antiphospholipid syndrome and central nervous system. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 602-608.	1.4	34
17	Antiphospholipid syndrome. <i>Lancet, The</i> , 2010, 376, 1498-1509.	13.7	916
18	Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. <i>Pathophysiology</i> , 2011, 18, 93-102.	2.2	19
19	Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. <i>Neurobiology of Aging</i> , 2011, 32, 272-279.	3.1	17

#	ARTICLE	IF	CITATIONS
20	Adverse Pregnancy Outcome in Antiphospholipid Antibodies Syndrome: Pathogenic Mechanisms and Clinical Management. , 0, , .		0
21	Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS). , 2011, , .		1
22	Clinical Presentation of Antiphospholipid Syndrome. , 2011, , 1001-1014.		0
23	Neuropsychiatric symptoms and brain structural alterations in Fabry disease. European Journal of Neurology, 2011, 18, 347-353.	3.3	44
24	Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmunity Reviews, 2011, 10, 214-217.	5.8	36
25	Pathophysiology of the antiphospholipid antibody syndrome. Autoimmunity Highlights, 2011, 2, 35-52.	3.9	50
26	Morbidity, Mortality, and Organ Damage in Patients with Antiphospholipid Syndrome. Journal of Rheumatology, 2012, 39, 516-523.	2.0	54
27	Early neuropsychiatric involvement in antiphospholipid syndrome. General Hospital Psychiatry, 2012, 34, 579.e1-579.e3.	2.4	9
28	Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a "systemic disease". Best Practice and Research in Clinical Rheumatology, 2012, 26, 79-90.	3.3	20
29	Cognitive Dysfunction and Antiphospholipid Antibodies. Current Rheumatology Reports, 2012, 14, 95-98.	4.7	9
30	Cognitive impairment in antiphospholipid syndrome: evidence from animal models. Clinical Rheumatology, 2012, 31, 403-406.	2.2	16
31	Síndrome antifosfolípido. Medicine, 2013, 11, 1975-1980.	0.0	0
32	Cognitive impairment and antiphospholipid syndrome: is paradoxical embolism the rule?. Neurological Research, 2013, 35, 890-894.	1.3	3
33	Antiphospholipid Antibodies, Brain Infarcts, and Cognitive and Motor Decline in Aging (ABICMA): Design of a Community-Based, Longitudinal, Clinical-Pathological Study. Neuroepidemiology, 2013, 40, 73-84.	2.3	14
34	Neurocognitive Function, Autoimmune Disorders and. , 2014, , 376-378.		0
35	Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus, 2014, 23, 1255-1258.	1.6	15
36	Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics. Journal of the Neurological Sciences, 2014, 346, 138-144.	0.6	24
37	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Research and Therapy, 2014, 16, 209.	3.5	99

#	ARTICLE	IF	CITATIONS
38	Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. <i>Translational Developmental Psychiatry</i> , 2015, 3, 25452.	0.3	11
39	Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2015, 105, 201-208.	3.6	14
40	Systemic Inflammation and the Brain: Novel Roles of Genetic, Molecular, and Environmental Cues as Drivers of Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 28.	3.7	248
41	Neuropsychiatric presentations of antiphospholipid antibodies. <i>Thrombosis Research</i> , 2015, 135, S56-S59.	1.7	28
42	COX-2 rs20417 Polymorphism Is Associated with Stroke and White Matter Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 1817-1822.	1.6	9
43	Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 29.	4.7	18
44	Antigliutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016, 7, 5.	4.8	30
45	The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus. <i>Reumatismo</i> , 2016, 68, 137-143.	0.9	14
46	Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients. <i>Arthritis Care and Research</i> , 2016, 68, 1655-1663.	3.4	24
47	Bilateral Sudden Sensorineural Hearing Loss in a Patient With Microangiopathic Antiphospholipid Syndrome. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2016, 12, 175-177.	0.3	3
48	Cognitive disorders and antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2016, 15, 1193-1198.	5.8	24
49	Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2016, 18, 11.	4.7	44
50	Anacusia sĀbita neurosensorial bilateral en un paciente con sĀndrome antifosfolĀpido primario microangiopĀtico. <i>ReumatologĀa ClĀnica</i> , 2016, 12, 175-177.	0.5	5
51	Nonclassification Criteria Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 131-144.	0.1	1
52	Prognosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 281-294.	0.1	0
53	Epidemiology of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 17-30.	0.1	17
54	Central Nervous System Manifestations of Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 547-560.	1.9	36
55	Fish oil attenuates neurologic severity of antiphospholipid syndrome in a mice experimental model. <i>Nutritional Neuroscience</i> , 2017, 20, 563-570.	3.1	4

#	ARTICLE	IF	CITATIONS
57	The cutaneous manifestations are significantly related to cerebrovascular in a Serbian cohort of patients with Hughes syndrome. <i>Lupus</i> , 2018, 27, 858-863.	1.6	6
58	Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 1001.	2.4	61
59	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414.	1.6	49
60	Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome. <i>Brain Structure and Function</i> , 2018, 223, 3463-3471.	2.3	4
61	The association between systemic lupus erythematosus and dementia A meta-analysis. <i>Dementia E Neuropsychologia</i> , 2018, 12, 143-151.	0.8	15
62	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , 2019, 104, 102311.	6.5	26
63	Acute Systemic Lupus Erythematosus and Antiphospholipid Syndrome With Cardiac Complications. <i>JACC: Case Reports</i> , 2019, 1, 240-242.	0.6	1
64	Cytokine secretion and the risk of depression development in patients with connective tissue diseases. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 302-316.	1.8	29
65	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 561-576.	2.6	20
67	Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 107.	3.7	18
68	AB0535...FACTORS RELATED TO FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS: A COHORT CROSS-SECTIONAL STUDY. , 2019, , .		0
69	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0
70	Clinical profiles and risk assessment in patients with antiphospholipid antibodies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 73-81.	3.0	10
71	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	3.4	37
72	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	3.4	39
73	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2020, 22, 51.	4.7	22
74	Case of catastrophic antiphospholipid syndrome presenting as neuroretinitis and vaso-occlusive retinopathy. <i>BMC Ophthalmology</i> , 2020, 20, 482.	1.4	4
75	The antiphospholipid syndrome " often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27

#	ARTICLE	IF	CITATIONS
76	Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS). <i>Rheumatology</i> , 2021, 60, 179-187.	1.9	6
77	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021, 198, 213-221.	1.7	39
78	Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin. <i>Clinical Rheumatology</i> , 2021, 40, 2559-2568.	2.2	4
79	Assessment of Cognitive Function in Systemic Lupus Erythematosus. , 2021, , 251-285.		0
80	Clinical presentation of antiphospholipid syndrome. , 2021, , 561-574.		0
81	Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2021, , .	1.9	13
82	Neurologic Manifestations of the Antiphospholipid Syndrome “an Update. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 41.	4.2	26
83	Assessment of the activity and organ damage in antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 101-106.	0.5	1
84	The brain in SLE. , 2021, , 231-255.		0
85	Neurocognitive Function in Systemic Autoimmune and Rheumatic Diseases. , 2010, , 355-372.		1
87	Neuropsychiatric Manifestations of Antiphospholipid Syndrome. , 2017, , 201-219.		2
88	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. <i>PLoS ONE</i> , 2013, 8, e55843.	2.5	83
89	Primary Antiphospholipid Syndrome: Unusual Presentation in a Seventy Two Year Old Man. <i>Libyan Journal of Medicine</i> , 2008, 3, 106-107.	1.6	1
94	Ischemic and nonischemic manifestations of antiphospholipid syndrome. <i>Kazan Medical Journal</i> , 2015, 96, 61-69.	0.2	2
97	Neurocognitive Function in Systemic Autoimmune and Rheumatic Diseases. , 2019, , 463-483.		0
98	Tongue Stiffness as Presentation of Antiphospholipid Syndrome: A Case Report. <i>Cureus</i> , 2020, 12, e8584.	0.5	0
99	Systemic Lupus Erythematosus, Mixed Connective Tissue Disease and Antiphospholipid Syndrome. , 2021, , 77-93.		1
100	ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT DISEASE IS A CAUSE OF ORGAN DAMAGES?. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 225-231.	1.0	3

#	ARTICLE	IF	CITATIONS
101	Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2020, 7, 180-183.	0.6	2
102	Clinical Management of Thrombotic Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 735.	2.4	11
103	Antiphospholipid syndromeâ€‘mediated acute cerebrovascular diseases and long-term outcomes. <i>Lupus</i> , 2022, 31, 228-237.	1.6	9
104	Neuropsychiatric Manifestations of Antiphospholipid Syndromeâ€‘A Narrative Review. <i>Brain Sciences</i> , 2022, 12, 91.	2.3	9
105	Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers. <i>Brain Sciences</i> , 2022, 12, 222.	2.3	2
106	An Update on Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2021, 23, 84.	4.7	20
107	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 589-600.	4.2	3
108	The clinical features and potential mechanisms of cognitive disorders in peripheral autoimmune and inflammatory diseases. <i>Fundamental Research</i> , 2022, , .	3.3	0
109	Antiphospholipid syndrome mimicking posterior cortical atrophy and the â€‘railroad trackâ€‘ sign on brain fluorodeoxyglucose-positron emission tomography. <i>Journal of the Neurological Sciences</i> , 2023, 448, 120615.	0.6	0
110	Non-pharmacological rehabilitation interventions for individuals with antiphospholipid syndrome: A scoping review. <i>Lupus</i> , 2024, 33, 101-110.	1.6	0
111	Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. <i>Rheumatology</i> , 2024, 63, S124-S136.	1.9	1
112	The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. <i>Rheumatology</i> , 2024, 63, S172-S185.	1.9	1